Abacavir and the potential risk of myocardial infarction

D Study Group1 describe results from their international observational cohort of 33347 HIV-1-infected individuals, which suggest an unexpected increased risk of myocardial infarction associated with abacavir therapy (relative rate 1-9, 95% Cl 147-2-45; P=0.0001). D. Analyses of relevant spontaneous...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 371; no. 9622; p. 1413
Main Authors Cutrell, Amy, Brothers, Cindy, Yeo, Jane, Hernandez, Jamie, Lapierre, Didier
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 26.04.2008
Elsevier Limited
Subjects
Anti-HIV Agents - adverse effects
Anti-HIV Agents - therapeutic use
Clinical trials
Clinical Trials as Topic
Dideoxynucleosides - adverse effects
Dideoxynucleosides - therapeutic use
Drug therapy
Heart attacks
HIV
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Internal Medicine
Myocardial infarction
Myocardial Infarction - chemically induced
Regulatory agencies
Risk
Risk Factors
Online AccessGet full text

Cover

More Information
Summary:D Study Group1 describe results from their international observational cohort of 33347 HIV-1-infected individuals, which suggest an unexpected increased risk of myocardial infarction associated with abacavir therapy (relative rate 1-9, 95% Cl 147-2-45; P=0.0001). D. Analyses of relevant spontaneous reports from the GSK and US Food and Drug Administration adverse event reporting system databases did not identify increased risk of myocardial ischaemic events associated with abacavir.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(08)60492-4